Journal of Vascular Surgery
Volume 51, Issue 2 , Pages 476-486 , February 2010

Management of diabetic foot problems

  • Jeffrey Kalish, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Jeffrey Kalish, MD, Fellow in Vascular & Endovascular Surgery, Beth Israel Deaconess Medical Center, 110 Francis St, LMOB 5B, Boston, MA 02215
    • ,
  • Allen Hamdan, MD

Received 24 June 2009 ,Accepted 12 August 2009.

References 

  1. Gibbons GW, Eliopoulos GM. Infection of the diabetic foot. In:  Kozak GP,  Campbell DR,  Frykberg RG,  Habershaw GM editor. Management of diabetic foot problems. 2nd edition. Philadelphia: WB Saunders; 1995;p. 121–129
  2. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2007. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htmAccessed: Jul 18, 2009
  3. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the U.S. Diabetes Care. 2003;26:1790–1795
  4. Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M, et al. Resource utilization and costs associated with the treatment of diabetic foot ulcers (Prospective data from the Eurodiale Study). Diabetologia. 2008;51:1826–1834
  5. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, et al. Diabetic foot disorders (A clinical practice guideline). (2006 revision) J Foot Ankle Surg. 2006;45(5 suppl):S1–S66
  6. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217–228
  7. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382–387
  8. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LMAmerican Diabetes Association. Preventive foot care in diabetes. Diabetes Care. 2004;27:S63–S64
  9. Boulton AJM, Vileikyte L, Ragnarson G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366:1719–1724
  10. Goldenberg SG, Alex M, Joshi RA, Blumenthal HT. Nonatheromatous peripheral vascular disease of the lower extremity in diabetes mellitus. Diabetes. 1959;8:261–273
  11. Strandness DE, Priest RE, Gibbons GW. Combined clinical and pathological study of diabetic and nondiabetic peripheral arterial disease. Diabetes. 1964;13:366–372
  12. LoGerfo FW, Coffman JD. Current concepts (Vascular and microvascular disease of the foot in diabetes. Implications for foot care). N Engl J Med. 1984;311:1615–1619
  13. Kozak GP, Giurini R. Diabetic neuropathies: lower extremities. In:  Kozak GP,  Campbell DR,  Frykberg RG,  Habershaw GM editor. Management of diabetic foot problems. 2nd ed.. Philadelphia: WB Saunders; 1995;p. 43–52
  14. Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med. 1973;288:831–836
  15. Boulton AJ, Scarpello JH, Ward JD. Venous oxygenation in the diabetic neuropathic foot: evidence of arteriovenous shunting?. Diabetologia. 1982;22:6–8
  16. Arora S, Smakowski P, Frykberg RG, Simeone LR, Freeman R, LoGerfo FW, et al. Differences in foot and forearm skin microcirculation in diabetic patients with and without neuropathy. Diabetes Care. 1998;21:1925–1934
  17. deMeijer VE, Van't Sant HP, Spronk S, Kusters FJ, den Hoed PT. Reference value of transcutaneous oxygen measurement in diabetic patients compared with nondiabetic patients. J Vasc Surg. 2008;48:382–388
  18. Leinonen H, Matikainen E, Juntunen J. Permeability and morphology of skeletal muscle capillaries in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1982;22:158–162
  19. Rayman G, Williams SA, Spencer PD, Smaje LH, Wise PH, Tooke JE. Impaired microvascular hyperaemic response to minor skin trauma in type I diabetes. Br Med J. 1986;292:1295–1298
  20. Parkhouse N, Le Quesne PM. Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med. 1988;318:1306–1309
  21. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. 1985;33:13–18
  22. Johannesson A, Larsson GU, Ramstrand N, Turkiewicz A, Wiréhn AB, Atroshi I. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. Diabetes Care. 2009;32:275–280
  23. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581
  24. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care. 1992;15:1926–1975
  25. Casellini CM, Vinik AI. Clinical manifestations and current treatment options for diabetic neuropathies. Endocr Pract. 2007;13:550–566
  26. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831–1836
  27. Serpell MG Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557–566
  28. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–2110
  29. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203–213
  30. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411–1420
  31. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–356
  32. Tan JS, Anderson JL, Watanakunakorn C, Phair JP. Neutrophil dysfunction in diabetes mellitus. J Lab Clin Med. 1975;85:26–33
  33. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes. 1974;23:9–15
  34. Lipsky BA. New developments in diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev. 2008;24(S1):S66–S71
  35. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the infectious diseases society of America's diabetic foot classification system. Clin Infect Dis. 2007;44:562–565
  36. Lavery LA, Peters EJ, Armstrong DG, Wendel CS, Murdoch DP, Lipsky BA. Risk factors for developing osteomyelitis in patients with diabetic foot wounds. Diabetes Res Clin Pract. 2009;83:347–352
  37. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis. 2008;47:519–527
  38. Lavery LA, Armstrong DG, Peters EJ, Lipsky BA. Probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?. Diabetes Care. 2007;30:270–274
  39. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers (A clinical sign of underlying osteomyelitis in diabetic patients). JAMA. 1995;273:721–723
  40. Marcus CD, Ladam-Marcus VJ, Leone J, Malgrange D, Bonnet-Gausserand FM, Menanteau BP. MR imaging of osteomyelitis and neuropathic osteoarthropathy in the feet of diabetics. Radiographics. 1996;16:1337–1348
  41. Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this patient with diabetes have osteomyelitis of the lower extremity?. JAMA. 2008;299:806–813
  42. Stein R, Hriljac I, Halperin JL, Gustavson SM, Teodorescu V, Olin JW. Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease. Vasc Med. 2006;11:29–33
  43. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94:3026–3049
  44. Potier L, Halbron M, Bouilloud F, Dadon M, Le Doeuff J, Ha Van G, et al. Ankle-to-brachial ratio index underestimates the prevalence of peripheral occlusive disease in diabetic patients at high risk for arterial disease. Diabetes Care. 2009;32:e44
  45. Hauser CJ, Klein SR, Mehringer CM, Appel P, Shoemaker WC. Superiority of transcutaneous oximetry in noninvasive vascular diagnosis in patients with diabetes. Arch Surg. 1984;119:690–694
  46. Carpenter JP, Baum RA, Holland GA, Barker CF. Peripheral vascular surgery with magnetic resonance angiography as the sole preoperative imaging modality. J Vasc Surg. 1994;20:861–869discussion 869-71
  47. Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol. 2008;190:736–741
  48. Toprak O, Cirit M, Yesil M, Bayata S, Tanrisev M, Varol U, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22:819–826
  49. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692–699
  50. Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53:617–627
  51. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491–499
  52. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006;48:924–930
  53. Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J. 2006;151:1032.e9–1032.e12
  54. Gibbons GW, Wheelock FC, Hoar CS, Rowbotham JL, Siembieda C. Predicting success of forefoot amputations in diabetics by noninvasive testing. Arch Surg. 1979;114:1034–1036
  55. Pomposelli FB, Arora S, Gibbons GW, Frykberg R, Smakowski P, Campbell DR, et al. Lower extremity arterial reconstruction in the very elderly: successful outcome preserves not only the limb but also residential status and ambulatory function. J Vasc Surg. 1998;28:215–225
  56. Hnath J, Roddy SP, Darling RC, Paty PS, Taggert JB, Mehta M. Comparative results of open lower extremity revascularization in nonagenarians. J Vasc Surg. 2009;49:1459–1464
  57. Tannenbaum GA, Pomposelli FB, Marcaccio EJ, Gibbons GW, Campbell DR, Freeman DV, et al. Safety of vein bypass grafting to the dorsal pedal artery in diabetic patients with foot infections. J Vasc Surg. 1992;15:982–988discussion 1989-90
  58. Treiman GS, Oderich GS, Ashrafi A, Schneider PA. Management of ischemic heel ulceration and gangrene: an evaluation of factors associated with successful healing. J Vasc Surg. 2000;31:1110–1118
  59. Berceli SA, Chan AK, Pomposelli FP, Gibbons GW, Campbell DR, Akbari CM, et al. Efficacy of dorsal pedal artery bypass in limb salvage for ischemic heel ulcers. J Vasc Surg. 1999;30:499–508
  60. Cook J, Cook E, Landsman AS, Basile P, Dinh T, Lyons T, et al. A retrospective assessment of partial calcanectomies and factors influencing postoperative course. J Foot Ankle Surg. 2007;46:248–255
  61. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet. 2003;361:1545–1551
  62. Lincoln NB, Radford KA, Game FL, Jeffcoate WJ. Education for secondary prevention of foot ulcers in people with diabetes: a randomised controlled trial. Diabeteologia. 2008;51:1954–1961
  63. Tyrrell W. Orthotic intervention in patients with diabetic foot ulceration. J Wound Care. 1999;8:530–532
  64. Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Oriani G, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer (A randomized study). Diabetes Care. 1996;19:1338–1343
  65. Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg. 2003;25:513–518
  66. Kessler L, Bilbault P, Ortega F, Grasso C, Passemard R, Stephan D, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 2003;26:2378–2382
  67. Duzgun AP, Satir HZ, Ozozan O, Saylam B, Kulah B, Coskun F. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg. 2008;47:515–519
  68. Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994;18:683–693
  69. Lipsky BA, Itani K, Norden CLinezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004;38:17–24
  70. Clay PG, Graham MR, Lindsey CC, Lamp KC, Freeman C, Glaros A. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. Am J Geriatr Pharmacother. 2004;2:181–189
  71. Harkless L, Boghossian J, Pollak R, Caputo W, Dana A, Gray S, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt). 2005;6:27–40
  72. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55:240–245
  73. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstrn DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005;366:1695–1703
  74. Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008;51:747–755
  75. Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection?. Clin Microbiol Infect. 2007;13:351–353
  76. Ellison MJ. Vancomycin, metronidazole, and tetracyclines. Clin Podiatr Med Surg. 1992;9:425–442
  77. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39:885–910
  78. Bamberger DM, Daus GP, Gerding DN. Osteomyelitis in the feet of diabetic patients: long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med. 1987;83:653–660
  79. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch Intern Med. 1999;159:851–856
  80. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med. 2003;114:723–728
  81. Senneville E, Lombart A, Beltrand E, Valette M, Legout L, Cazaubiel M, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care. 2008;31:637–642
  82. Game FL, Jeffcoate WJ. Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia. 2008;51:962–967
  83. Venkatesan P, Lawn S, Macfarlane RM, Fletcher EM, Finch RG, Jeffcoate WJ. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med. 1997;14:487–490
  84. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997;25:1318–1326
  85. Ha Van G, Siney H, Danan JP, Sachon C, Grimaldi A. Treatment of osteomyelitis in the diabetic foot (Contribution of conservative surgery). Diabetes Care. 1996;19:1257–1260
  86. Gibbons GW. The diabetic foot: amputations and drainage of infection. J Vasc Surg. 1987;5:791–793
  87. Sheahan MG, Hamdan AD, Veraldi JR, McArthur CS, Skillman JJ, Campbell DR, et al. Lower extremity minor amputations: the roles of diabetes mellitus and timing of revascularization. J Vasc Surg. 2005;42:476–480
  88. Vikatmaa P, Juutilainen V, Kuukasjarvi P, Malmivaara A. Negative pressure wound therapy: a systematic review on effectiveness and safety. Eur J Vasc Endovasc Surg. 2008;36:438–448
  89. Armstrong DG, Lavery LADiabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366:1704–1710
  90. Apelqvist J, Armstrong DG, Lavery LA, Boulton AJ. Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds. Am J Surg. 2008;195:782–788
  91. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. 2008;31:631–636
  92. Ciavarella A, Silletti A, Mustacchio A, Gargiulo M, Galaverni MC, Stella A, et al. Angiographic evaluation of the anatomic pattern of arterial obstructions in diabetic patients with critical limb ischemia. Diabet Metab. 1993;19:586–589
  93. Pomposelli FB, Jepsen SJ, Gibbons GW, Campbell DR, Freeman DV, Miller A, et al. Efficacy of the dorsal pedal bypass for limb salvage in diabetic patients: short-term observations. J Vasc Surg. 1990;11:745–751
  94. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, Sheahan M, Campbell DR, et al. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. J Vasc Surg. 2003;37:307–315
  95. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742–751
  96. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD): TASC Working Group. J Vasc Surg. 2000;31:S1–S296
  97. Goshima KR, Mills JL, Hughes JD. A new look at outcomes after Infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. J Vasc Surg. 2004;39:330–335
  98. Nicoloff AD, Taylor LM, McLafferty RB, Moneta GL, Porter JM, et al. Patient recovery after infrainguinal bypass grafting for limb salvage. J Vasc Surg. 1998;27:256–263
  99. DeRubertis BG, Pierce M, Ryer EJ, Trocciola S, Kent KC, Faries PL. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg. 2008;47:101–108
  100. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. BASIL trial participants Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934
  101. Beard JD. Which is the best revascularization for critical limb ischemia: Endovascular or open surgery?. J Vasc Surg. 2008;48(6 suppl):11S–16S
  102. Giles KA, Pomposelli FB, Hamdan AD, Blattman SB, Panossian H, Schermerhorn ML. Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg. 2008;48:128–136
  103. Lantis JC, Conte MS, Belkin M, Whittemore AD, Mannick JA, Donaldson MC. Infrainguinal bypass grafting in patients with end-stage renal disease: improving outcomes?. J Vasc Surg. 2001;33:1171–1178
  104. Ramdev P, Rayan SS, Sheahan M, Hamdan AD, Logerfo FW, Akbari CM, et al. A decade experience with infrainguinal revascularization in a dialysis-dependent patient population. J Vasc Surg. 2002;36:969–974
  105. Korn P, Hoenig SJ, Skillman JJ, Kent KC. Is lower extremity revascularization worthwhile in patients with end- stage renal disease?. Surgery. 2000;128:472–479
  106. Johnson BL, Glickman MH, Bandyk DF, Esses GE. Failure of foot salvage in patients with end-stage renal disease after surgical revascularization. J Vasc Surg. 1995;22:280–286
  107. Aulivola B, Gargiulo M, Bessoni M, Rumolo A, Stella A. Infrapopliteal angioplasty for limb salvage in the setting of renal failure: do results justify its use?. Ann Vasc Surg. 2005;19:762–768
  108. Graziani L, Silvestro A, Bertone V, Manara E, Alicandri A, Parrinello G, et al. Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral arterial disease. Nephrol Dial Transplant. 2007;22:1144–1199
  109. Abou-Zamzam AM, Gomez NR, Molkara A, Banta JE, Teruya TH, Killeen JD, et al. A prospective analysis of critical limb ischemia: factors leading to major primary amputation versus revascularization. Ann Vasc Surg. 2007;21:458–463
  110. Nehler MR, Coll JR, Hiatt WR. Functional outcome in a contemporary series of major lower extremity amputations. J Vasc Surg. 2003;38:7–14
  111. Toursarkissian B, Shireman PK, Harrison A, D'Ayala M, Schoolfield J, Sykes MT. Major lower-extremity amputation: contemporary experience in a single Veterans Affairs institution. Am Surg. 2002;68:606–610

 Competition of interest: none.

 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

PII: S0741-5214(09)01684-X

doi: 10.1016/j.jvs.2009.08.043

Journal of Vascular Surgery
Volume 51, Issue 2 , Pages 476-486 , February 2010

Article Tools